Stifel Upgrades Puma Biotechnology (PBYI) to Buy After Neratinib NDA Accepted

September 20, 2016 4:50 PM EDT
Get Alerts PBYI Hot Sheet
Price: $43.55 -0.57%

Rating Summary:
    7 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade PBYI Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Stifel upgraded Puma Biotechnology (NYSE: PBYI) from Hold to Buy with a price target of $88.00 (from $61.00) after the FDA accepted for review the neratinib New Drug Application in the extended adjuvant treatment, which significantly de-risks the story.

Analyst Thomas Shrader commented, "Puma today announced that the FDA has accepted for review the neratinib New Drug Application in the extended adjuvant treatment. For some time, we have viewed this event as unusually important for this drug due the procedural irregularities in the ExteNet trial that might have caused it to no longer be considered as “registrational”. However, investors appear to have been less cautious and the stock has run up considerably prior to today’s news to levels, which we believe reflect a reasonable commercial scenario for neratinib. We expect an ODAC panel for neratinib in the extended adjuvant setting as there are no other drugs approved in this setting for Her2 amplified disease. We expect some discussion of the possibility of waiting for OS data before approval, but overall we believe physicians are warming to this drug whose efficacy matches the greatest area of unmet need (HR+ patients) with a safety profile that increasingly looks to be under reasonable control. Based on today’s news, we are raising our probability of approval from 75% to 90%. As a result we raise our price target from $61 to $88 and raise our rating from Hold to Buy."

For an analyst ratings summary and ratings history on Puma Biotechnology click here. For more ratings news on Puma Biotechnology click here.

Shares of Puma Biotechnology closed at $58.95 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot Upgrades, Upgrades

Related Entities


Add Your Comment